Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy

Journal of Neurology Neurosurgery and Psychiatry

Volumn 65, Issue 1, 1998, Pages 34-41

  Baldeweg, Torsten ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

AIDS; Cerebral toxoplasmosis; CNS lymphoma; Dementia; Progressive multifocal leukoencephalopathy; Zidovudine

Indexed keywords

DIDANOSINE; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DEMENTIA; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEUROPROTECTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETROSPECTIVE STUDY; RISK; TOXOPLASMOSIS;

EID: 0031838185     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.65.1.34     Document Type: Article

References (3)

1. Simpson DM, Tagliati M. Neurologic manifestations of HIV infection. Ann Intern Med 1994;121:769-85.
2. Price RW. Neurological complications of HIV infection. Lancet 1996;348:445-52.
3. Portegies P, De Gans J, Lange JMA, et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ 1989;299:819-21.